Status:
WITHDRAWN
Lucentis for New Onset Neovascular Glaucoma
Lead Sponsor:
University of Illinois at Chicago
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Glaucoma
New Onset Glaucoma
Eligibility:
All Genders
21+ years
Phase:
PHASE1
PHASE2
Brief Summary
Neovascular glaucoma is a potentially debilitating disease of the eye. Vascular eye disease such as diabetes and vein occlusions can cause the retina to release factors that promote the growth of abno...
Detailed Description
Hypothesis: Intravitreal injection of Lucentis prior to conventional treatment for neovascular glaucoma improves overall outcome compared to conventional treatment alone. Specific Aims: To determin...
Eligibility Criteria
Inclusion
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age \> 21 years
- Diagnosis of neovascular glaucoma (angle neovascularization with or without iris neovascularization and IOP \> 21 mm Hg and \> 5 mm Hg IOP compared to the fellow eye).
- Neovascular glaucoma secondary to retinal ischemia (central retinal vein occlusion, proliferative diabetic retinopathy, ocular ischemic syndrome, etc.)
Exclusion
- Pregnancy (positive pregnancy test) or lactation or pre-menopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.
- Prior enrollment in the study
- Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
- Participation in another simultaneous medical investigation or trial
- \> 270 degrees of closed trabecular meshwork (closure secondary to peripheral anterior synechiae)
- History of active inflammatory, infectious, or idiopathic keratitis precluding view of the anterior segment structures.
- Previous intravitreal injections of ranibizumab or bevacizumab in either eye.
Key Trial Info
Start Date :
January 4 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00727038
Start Date
January 4 2008
End Date
May 15 2009
Last Update
February 17 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.